ABSTRACT
Clinical psychiatry can benefit greatly from recent advances in pharmacogenomic research. The application of pharmacogenomic strategies to antipsychotic treatment will have obvious advantages including selecting the drug most likely to produce beneficial results, according to the genetic predisposition of the individual. The main benefits of this will be better recovery levels and the reduction of adverse reactions. Additional benefits include the validation of therapeutic targets to assist the development of more selective and improved drugs. Recent studies supporting this optimistic view include the identification of genetic variants associated with the development of side effects and the development of a test for predicting treatment response using genetic information.
